 |
|
|
|
|
|
|
|
 |
Results for 'Wyeth' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Wyeth
PharmaVitae Profile
|
July 2008 |
£3010 |
100 % |
Wyeth - SWOT Analysis
|
June 2008 |
£66 |
97 % |
Wyeth Prospects to 2010
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
97 % |
Wyeth -Therapeutic Competitors
|
February 2008 |
£175 |
97 % |
Wyeth -Detailed Product Pipeline
|
February 2008 |
£375 |
96 % |
Wyeth Partnering Guide 2008
|
July 2021 |
£195 |
96 % |
Wyeth -Deals & Alliances Report
|
February 2008 |
£300 |
96 % |
Wyeth -Financial Company Report
|
February 2008 |
£175 |
96 % |
Wyeth IMS Company Profile
|
November 2007 |
£510 |
96 % |
Wyeth: PharmaVitae Profile
PharmaVitae Profile
|
January 2007 |
£3000 |
49.5 % |
Wyeth - OTC Healthcare – World
|
January 2008 |
£195 |
34.65 % |
Tigecycline: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
34 % |
Tazobactam: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
32 % |
Clinical Outsourcing Sponsors Forcing Market Change
|
June 2005 |
£1945 |
31.85 % |
Arqule Inc
Premium Company Profile
|
January 2008 |
£265 |
24.5 % |
PharmaVitae 2005: MedImmune Global Analysis
|
July 2005 |
£2005 |
23 % |
Commercial Insight: Depression
Atypical lifecycle management strategy rejuvenates depression market
|
June 2007 |
£7600 |
22.5 % |
PharmaVitae 2005: MedImmune Global and US Analysis
|
July 2005 |
£3000 |
22.5 % |
OTC Pharmaceuticals in Japan
|
January 2008 |
£125 |
22.4 % |
OTC Pharmaceuticals in Australia
|
January 2008 |
£125 |
22.4 % |
OTC Pharmaceuticals in the United States
|
December 2007 |
£125 |
21 % |
Pharmaceuticals in the United Kingdom
|
December 2007 |
£125 |
21 % |
Venlafaxine: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
21 % |
Lansoprazole: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20.5 % |
Pantoprazole: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20 % |
Venlafaxine: Pipeline™ Developer
Patent Report
|
Ongoing |
£2120 |
19.5 % |
Pharma R&D Fact Book, The
2006
|
November 2007 |
£595 |
19.5 % |
Lansoprazole: Pipeline™ Developer
Patent Report
|
Ongoing |
£2120 |
18.5 % |
World OTC Pharmaceutical Markets
Self-Medication, Developing and Petro-Rich Economies, BTC and Other Growth Trends
|
May 2008 |
£2085 |
18.5 % |
Pantoprazole: Pipeline™ Developer
Patent Report
|
Ongoing |
£2460 |
18.5 % |
All Change in the US Pharma Market?
|
June 2008 |
£995 |
18 % |
Anti-Aging Products to 2009
|
June 2005 |
£2740 |
17.5 % |
Moxidectin (Vet): Pipeline™ Developer
Patent Report
|
Ongoing |
£2460 |
17.5 % |
Defending Brand Revenue
Pharmaceutical Lifecycle Management Planning
|
July 2005 |
£2530 |
16 % |
Smoking Cessation Aids in Ireland
|
January 2006 |
£450 |
15.05 % |
Corporate Security
Protecting Productivity
|
December 2007 |
£4560 |
15 % |
Combating Generics 2008
Counter-Generics Strategy, Tactics and Execution
|
December 2007 |
£5015 |
15 % |
Crisis Management And Corporate Reputation
Counter-Generics Strategy, Tactics and Execution
|
November 2007 |
£4560 |
15 % |
NBTY Inc - OTC Healthcare - World
|
January 2008 |
£195 |
14.7 % |
Eye Care in the US
|
June 2008 |
£450 |
14.7 % |
Medicated Skin Care in the United Kingdom
|
July 2007 |
£450 |
14.7 % |
Medicated Skin Care in the Czech Republic
|
November 2007 |
£450 |
14.7 % |
Wound Treatments in Indonesia
|
January 2008 |
£450 |
14.7 % |
Eye Care in Denmark
|
December 2007 |
£450 |
14.7 % |
Wound Treatments in the US
|
June 2008 |
£450 |
14.7 % |
Stakeholder Opinions: Hormonal Contraceptives
New directions in a competitive market
|
November 2006 |
£2005 |
14.5 % |
Educating the Market: Creating Value Through Support of Continuing Medical Education
|
March 2008 |
£2260 |
14.5 % |
Digestive Remedies in the US
|
June 2008 |
£450 |
14.35 % |
Analgesics in the US
|
June 2008 |
£450 |
14.35 % |
Wound Treatments in Ireland
|
August 2007 |
£450 |
14.35 % |
Medicated Skin Care in Venezuela
|
February 2008 |
£450 |
14.35 % |
Medicated Skin Care in Vietnam
|
January 2008 |
£450 |
14.35 % |
Eye Care in China
|
September 2007 |
£450 |
14.35 % |
Wound Treatments in Italy
|
December 2007 |
£450 |
14.35 % |
Medicated Skin Care in the US
|
June 2008 |
£450 |
14 % |
Follicle Stimulating Hormone (FSH)
Competitor Analysis
|
November 2008 |
£125 |
14 % |
Eye Care in United States
|
May 2006 |
£450 |
14 % |
Wound Treatments in Japan
|
September 2007 |
£450 |
14 % |
Vitamins and Dietary Supplements in the US
|
June 2008 |
£450 |
14 % |
NRT Smoking Cessation Aids in the US
|
June 2008 |
£450 |
14 % |
Merck KGaA - OTC Healthcare - World
|
January 2008 |
£195 |
14 % |
Global Pharmaceuticals - Yearly Update 2006
|
July 2007 |
£600 |
13.65 % |
Eye Care in Brazil
|
August 2007 |
£450 |
13.65 % |
Wound Treatments in Colombia
|
October 2004 |
£450 |
13.65 % |
Cough, Cold and Allergy (Hay Fever) Remedies in the US
|
June 2008 |
£450 |
13.65 % |
Digestive Remedies in United States
|
May 2006 |
£450 |
13.65 % |
NRT Smoking Cessation Aids in United States
|
May 2006 |
£450 |
13.65 % |
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
|
July 2008 |
£7700 |
13.5 % |
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
|
July 2008 |
£7700 |
13.5 % |
Pipeline and Commercial Insight: Alzheimer's Disease
Scenario Forecasts Reveal Vast Market Potential
|
March 2008 |
£7600 |
13.5 % |
Therapeutic/Diagnostic Devices for Neurological Disorders
|
March 2007 |
£3160 |
13.5 % |
Pipeline Insight: Depression
Novel drugs to grow third-line market
|
March 2007 |
£6000 |
13.5 % |
Eye Care in China
|
July 2008 |
£450 |
13.3 % |
NRT Smoking Cessation Aids in China
|
July 2008 |
£450 |
13.3 % |
Wound Treatments in China
|
July 2008 |
£450 |
13.3 % |
Vitamins And Dietary Supplements in United States
|
May 2006 |
£450 |
13.3 % |
Medicated Skin Care in United States
|
May 2006 |
£450 |
13.3 % |
Pipeline Insight: Schizophrenia
|
July 2006 |
£6330 |
13 % |
Maintaining a Competitive Edge in Pharmaceutical Public Affairs: Benchmarking the Resources Required to Serve the U.S. Market
|
February 2008 |
£2190 |
13 % |
Commercial Insight: Transplantation
|
June 2006 |
£8695 |
13 % |
Pipeline Insight: Bipolar Disorder
New treatments for bipolar depression set to drive near-term growth
|
September 2006 |
£6495 |
13 % |
Medicated Skin Care in China
|
July 2008 |
£450 |
12.95 % |
Wound Treatment in the United Kingdom
|
December 2005 |
£450 |
12.95 % |
Vaccines Market Outlook, The
Market analysis of future growth and leading players by sector
|
January 2005 |
£1495 |
12.95 % |
Analgesics in the UK
|
March 2006 |
£450 |
12.95 % |
Digestive Remedies in China
|
July 2008 |
£450 |
12.95 % |
Analgesics in China
|
July 2008 |
£450 |
12.95 % |
Eye Care in Ireland
|
July 2006 |
£450 |
12.95 % |
Cough, Cold And Allergy (Hay Fever) Remedies in United States
|
May 2006 |
£450 |
12.95 % |
Analgesics in the United Kingdom
|
August 2006 |
£450 |
12.6 % |
The CNS Market Outlook to 2010
|
May 2005 |
£1495 |
12.6 % |
Eye Care in the United Kingdom
|
August 2006 |
£450 |
12.6 % |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
August 2008 |
£3800 |
12.6 % |
Anti Infectives, Vol II: Antibacterials
|
April 2007 |
£1950 |
12.6 % |
Wound Treatments in the United Kingdom
|
August 2006 |
£450 |
12.6 % |
Smoking Cessation Aids in the United Kingdom
|
December 2005 |
£450 |
12.6 % |
Wound Treatment in Colombia
|
November 2005 |
£450 |
12.6 % |
CNS Market Outlook to 2011, The
|
November 2006 |
£1495 |
12.6 % |
Analgesics in Colombia
|
November 2005 |
£450 |
12.6 % |
Eye Care in Colombia
|
November 2005 |
£450 |
12.6 % |
Analgesics in Ireland
|
July 2006 |
£450 |
12.6 % |
Digestive Remedies in the UK
|
March 2006 |
£450 |
12.6 % |
Vitamins and Dietary Supplements in China
|
July 2008 |
£450 |
12.6 % |
Medicated Skin Care in Colombia
|
October 2004 |
£450 |
12.6 % |
Vitamins And Dietary Supplements in the UK
|
March 2006 |
£450 |
12.6 % |
Rewarding & Recognizing Top-Performing Sales People
|
March 2008 |
£2260 |
12.5 % |
Pipeline Insight: Asthma/COPD
Targeted therapies on the horizon
|
November 2006 |
£6000 |
12.5 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
12.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in China
|
July 2008 |
£450 |
12.25 % |
NRT Smoking Cessation Aids in Ireland
|
July 2006 |
£450 |
12.25 % |
The CNS Market Outlook to 2011
|
November 2006 |
£1495 |
12.25 % |
Medicated Skincare in the United Kingdom
|
December 2005 |
£450 |
12.25 % |
Digestive Remedies in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
The Pharmaceutical Market: Ireland
|
November 2007 |
£595 |
12.25 % |
Medicated Skin Care in the UK
|
March 2006 |
£450 |
12.25 % |
NRT Smoking Cessation Aids in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
South Korea Pharmaceuticals and Healthcare Report Q3 2007
|
September 2007 |
£360 |
12 % |
Immunogenicity to Biologics
Implications Of Reactions Against Biotech Drugs
|
November 2007 |
£1450 |
12 % |
Vitamins and Dietary Supplements in the United Kingdom
|
August 2006 |
£450 |
11.9 % |
Cough, Cold and Allergy (Hayfever) Remedies in the United Kingdom
|
December 2005 |
£450 |
11.9 % |
Vitamins and Dietary Supplements in Colombia
|
November 2005 |
£450 |
11.9 % |
Medicated Skin Care in Ireland
|
July 2006 |
£450 |
11.9 % |
Medicated Skin Care in the United Kingdom
|
August 2006 |
£450 |
11.9 % |
Cough, Cold And Allergy (Hay Fever) Remedies in the UK
|
March 2006 |
£450 |
11.9 % |
Digestive Remedies in Colombia
|
November 2005 |
£450 |
11.9 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Colombia
|
October 2004 |
£450 |
11.9 % |
Cough, Cold and Allergy (Hay Fever) Remedies in the United Kingdom
|
August 2006 |
£450 |
11.55 % |
World Pharmaceutical Market (2007)
|
November 2006 |
£485 |
11.55 % |
The Gastrointestinal Market Outlook to 2010
|
January 2006 |
£1495 |
11.55 % |
The Gastrointestinal Market Outlook To 2012
|
October 2007 |
£1495 |
11.55 % |
OTC Pharmaceuticals
Global Industry Guide
|
February 2008 |
£790 |
11.2 % |
CNS Market Trends, 2007 to 2010
Key Market Forecasts and Growth Opportunities
|
June 2007 |
£995 |
11.2 % |
Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012; The
|
January 2006 |
£1900 |
11.2 % |
Lymphoma
A Therapeutic & Competitive Insight
|
May 2006 |
£1660 |
11.2 % |
South Korea Pharmaceuticals & Healthcare
|
December 2006 |
£395 |
11 % |
Biotech Drug Delivery Systems
Key Company Intelligence & Market Outlook to 2012
|
February 2007 |
£1299 |
11 % |
The CNS Market Outlook To 2012
|
October 2007 |
£1495 |
10.85 % |
Pharmaceutical Market Trends, 2007-2011
Key market forecasts and growth opportunities (2nd Edition)
|
November 2007 |
£995 |
10.85 % |
Autoimmune Market Outlook to 2012
|
August 2007 |
£1495 |
10.85 % |
New Drug Futures: Central Nervous System Chapter
|
May 2006 |
£695 |
10.85 % |
World Generics Market 2006-2011; The
|
May 2006 |
£1499 |
10.5 % |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1660 |
10.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Japan
|
September 2007 |
£450 |
10.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Indonesia
|
January 2008 |
£450 |
10.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Ireland
|
August 2007 |
£450 |
10.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Mexico
|
February 2008 |
£450 |
10.5 % |
Scrip R&D Databook 2006
|
January 2006 |
£1295 |
10.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Hong Kong
|
October 2007 |
£450 |
10.5 % |
China Pharmaceutical Industry Report (Merger & Reorganization), 2006
|
August 2006 |
£1500 |
10.5 % |
Animal Health Products Antibacterials Markets
|
May 2008 |
£1305 |
10.5 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Italy
|
November 2007 |
£450 |
10.15 % |
Women's Health Market Outlook to 2011
|
May 2007 |
£1495 |
10.15 % |
The Women's Health Market Outlook to 2011
|
April 2007 |
£1495 |
10.15 % |
Vaccines
The World Market
|
February 2007 |
£2605 |
10 % |
Prostate and Breast Cancer- New Treatments & Developmental Progress
|
March 2007 |
£2510 |
10 % |
Vaccines: The World Market
|
February 2007 |
£2605 |
10 % |
Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006
Market Insights and Trends in a Primary Import Destination
|
August 2006 |
£900 |
10 % |
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets
|
August 2004 |
£420 |
10 % |
Pharmaceutical Companies Performance Tables 2005
|
November 2006 |
£295 |
9.8 % |
Cough, Cold and Allergy (Hay Fever) Remedies in India
|
February 2008 |
£450 |
9.8 % |
Product Lifecycle Management, 2006
|
May 2006 |
£1499 |
9.5 % |
World Neurodegeneratives Disease Markets
|
February 2005 |
£1499 |
9.5 % |
Pharmaceutical Product Approval Trends, 2007
Key Market Benchmarks And Strategic Insights
|
December 2007 |
£1299 |
9.45 % |
Scrip Yearbook 2007
23rd Edition (2 Volumes)
|
January 2006 |
£895 |
9.45 % |
Partnering with Biopharma
The definitive guide to bigpharma partnering interests, contacts & agreements
|
July 2001 |
£1495 |
9.45 % |
Powering Discovery through Target Evaluation
Moving Beyond the Validation Paradigm
|
August 2005 |
£1950 |
9.1 % |
Breast Cancer
The Latest R&D Trends
|
February 2007 |
£1660 |
9 % |
Partneringdesk deals and alliances in musculoskeletal diseases
|
April 2006 |
£1250 |
9 % |
The CNS Market Outlook to 2013
Competitive landscape, pipeline analysis and growth opportunities
|
September 2008 |
£1995 |
8.75 % |
Pipeline And Commercial Insight
Pediatric And Adolescent Vaccines
|
July 2007 |
£8000 |
8.75 % |
Financial Markets Research: ASCO Review Part II
A summary of highlights presented at the ASCO 2006 Annual Meeting
|
August 2006 |
£2195 |
8.75 % |
The Global Drug Delivery Market
Research Trends and Market Outlook
|
May 2006 |
£1305 |
8.75 % |
Women's Health: Diagnostic Testing
|
August 2008 |
£1185 |
8.75 % |
Cordis Medical Device Company Intelligence Report
|
November 2007 |
£295 |
8.75 % |
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023
|
June 2008 |
£1499 |
8.4 % |
The Global Anti-Infectives Market Outlook to 2011
|
June 2007 |
£1495 |
8.4 % |
Bigpharma Agreements Handbook
Partnering Agreements
|
September 2001 |
£2195 |
8.4 % |
DePuy Medical Device Company Intelligence Report
|
December 2007 |
£295 |
8.4 % |
Takeda: Pipeline, Products, Performance, Potential
|
November 2007 |
£595 |
8.4 % |
Bigpharma Partnering Agreements
|
March 2001 |
£1195 |
8.4 % |
Pakistan Pharmaceuticals and Healthcare Report Q3 2008
|
September 2008 |
£425 |
8.4 % |
Pakistan Pharmaceuticals & Healthcare
|
January 2007 |
£395 |
8.05 % |
Vaccines Market Insight
Products, Pipelines & Market Outlook
|
January 2007 |
£1095 |
8.05 % |
Emerging Diabetes Drugs
Competitor Analysis
|
November 2008 |
£415 |
8.05 % |
Innovations and Trends in Clinical Trials
Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
|
March 2007 |
£1465 |
8.05 % |
Global Vaccine Market Outlook (2007-2010)
|
June 2007 |
£1045 |
8.05 % |
Bigpharma Dealmaking and Agreements Handbook 2007
Companies, Contacts & Partnering Agreements
|
September 2007 |
£1195 |
8.05 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
8 % |
CNS Generic Drugs: Prospects and Opportunities to 2012
|
April 2008 |
£995 |
8 % |
Urinary Tract Agents Report 2005
|
April 2005 |
£1499 |
8 % |
Global Image Dermatology Drug Market, 2005-2012, The
High-Growth Opportunities in Aesthetic Medicine
|
November 2005 |
£1900 |
8 % |
Ion Channel Drug Discovery
Therapeutic Opportunities & Technology Progress
|
May 2004 |
£850 |
8 % |
Model Animal Systems
Emerging Applications and Commercial Opportunities in Drug Discovery and Development
|
June 2004 |
£1946 |
7.7 % |
Nycomed
Pipeline Products Performance Potential
|
October 2007 |
£595 |
7.7 % |
The Global Antibacterials Market
R&D Pipelines, Market Analysis and Competitive Landscape
|
August 2007 |
£810 |
7.7 % |
Veterinary Health Markets
|
August 2007 |
£2215 |
7.7 % |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2510 |
7.5 % |
Pre-clinical Stage Partnering Agreements in Biopharma
|
October 2010 |
£1195 |
7.35 % |
Indian Pharmaceutical Industry, The:
|
March 2005 |
£3335 |
7.35 % |
Amgen
Profile, Patents and Pipeline
|
August 2005 |
£325 |
7.35 % |
Amgen: Profile, Patents and Pipeline
Profile, Patents and Pipeline
|
August 2005 |
£325 |
7.35 % |
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012
|
February 2007 |
£1499 |
7.35 % |
Osteoporosis & Bone Metabolism Disorders Market
2008-2023
|
August 2008 |
£1499 |
7.35 % |
Pharmaceutical R&D Productivity
The Path to Innovation
|
October 2005 |
£1945 |
7.35 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
7 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
7 % |
The Pharmaceutical Market: China
|
July 2008 |
£595 |
7 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
7 % |
New Drug Futures: Musculoskeletal Chapter
|
May 2006 |
£695 |
7 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
7 % |
China Pharmaceutical Industry Report (Merger and Reorganization), 2006-2007
|
January 2007 |
£1110 |
7 % |
Partneringreview 2006
|
February 2006 |
£2195 |
7 % |
Bigpharma Dealmaking Handbook
Companies & Contacts
|
September 2001 |
£2195 |
6.65 % |
Solvay Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
6.65 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
6.5 % |
New Drug Futures: Anti-Infective Chapter
|
May 2006 |
£695 |
6.3 % |
Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics
|
November 2011 |
£1195 |
6.3 % |
CNS Drug Discoveries
What the Future Holds
|
November 2006 |
£1995 |
6.3 % |
Distribution Agreements in Biopharma
|
April 2001 |
£1195 |
6.3 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
6 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3400 |
6 % |
Women's Reproductive Disorders Therapeutics 2008-2018
|
